Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial
-
Altmetric Citations
He, Jing; Zhang, Ruijun; Shao, Miao; Zhao, Xiaozhen; Miao, Miao; Chen, Jiali; Liu, Jiajia; Zhang, Xiaoying; Zhang, Xia; Jin, Yuebo; Wang, Yu; Zhang, Shilei; Zhu, Lei; Jacob, Alexander; Jia, Rulin; You, Xujie; Li, Xue; Li, Chun; Zhou, Yunshan; Yang, Yue; Ye, Hua; Liu, Yanying; Su, Yin; Shen, Nan; Alexander, Jessy; Guo, Jianping; Ambrus, Julian; Lin, Xin; Yu, Di; Sun, Xiaolin; Li, Zhanguo
Description
Objectives Open-labelled clinical trials suggested that low-dose IL-2 might be effective in treatment of systemic lupus erythematosus (SLE). A double-blind and placebocontrolled trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy. Methods A randomised, double-blind and placebocontrolled clinical trial was designed to treat 60 patients with active SLE. These patients received either IL-2 (n=30) or placebo (n=30) with standard treatment for 12 weeks, and...[Show more]
Collections | ANU Research Publications |
---|---|
Date published: | 2020 |
Type: | Journal article |
URI: | http://hdl.handle.net/1885/282774 |
Source: | Annals of the Rheumatic Diseases |
DOI: | 10.1136/annrheumdis-2019-215396 |
Access Rights: | Open Access |
Download
File | Description | Size | Format | Image |
---|---|---|---|---|
141.full.pdf | 1.28 MB | Adobe PDF |
This item is licensed under a Creative Commons License
Updated: 17 November 2022/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator